Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort.

Institut National de la Santé et de la Recherche Médicale (INSERM) U897.
Clinical Infectious Diseases (Impact Factor: 9.42). 09/2009; 49(7):1109-16. DOI: 10.1086/605594
Source: PubMed

ABSTRACT Human immunodeficiency virus (HIV)-infected patients are at higher risk of malignancies. In addition to traditional determinants, a specific deleterious effect of HIV and immunodeficiency is speculated. We aimed at studying the association between immunological and virological characteristics of HIV-infected patients in care and the risk of acquired immunodeficiency syndrome (AIDS)-defining and non-AIDS-defining malignancies.
Patients consecutively enrolled in the hospital-based Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort were included if the duration of follow-up was >3 months during the period 1998-2006. Multivariate modeling used an extended Cox proportional hazards model for time-dependent covariates and delayed entry.
The 4194 patients included in the study developed 251 first malignancies during 22,389 person-years. A higher incidence of AIDS-defining malignancies (107 cases) was independently associated with (1) both longer and current exposures to a plasma HIV RNA level >500 copies/mL (hazard ratio [HR], 1.27 per year [P<.001] and 3.30 [P<.001], respectively) and (2) both longer and current exposure to a CD4(+) cell count <200 cells/mm(3) (HR, 1.36 per year [P<.001] and 6.33 [P<.001], respectively). A higher incidence of non-AIDS-defining malignancies (144 cases) was independently associated with longer and current exposure to a CD4(+) cell count <500 cells/mm(3) (HR, 1.13 per year [P=.01] and 2.07 [P<.001], respectively) and male sex (HR, 1.69; P=.02) but not with plasma HIV RNA level (P=.49 and P=.10 for cumulative and current exposures, respectively).
Uncontrolled plasma HIV RNA level was independently associated with a higher likelihood of developing AIDS-defining malignancies, whereas immunosuppression was associated with a higher risk of developing any type of malignancies. Antiretroviral treatment should aim at reaching and maintaining a CD4(+) count >500 cells/mm(3) to prevent the occurrence of malignancy, this should be integrated to malignancy-prevention policies.

  • AIDS (London, England) 03/2014; 28(6):925-6. · 6.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: AIDS was the cause of the majority of deaths from HIV infection before 1996 but since the introduction of antiretroviral therapies the causes of mortality have changed considerably. In 2010, 75 % of deaths were due to diseases other than AIDS, the majority being cancers. Lung cancer is the most common in terms of both incidence and mortality. It shows specific features when compared to the general population: there is an excess risk due to heavy smoking but also probably due to immunosuppression. The age of onset is younger and the prognosis worse than in the general population. Management is difficult, partly due to the aggressive nature of the tumor and partly to co-morbidities and potential interactions between anticancer and antiretroviral therapies. A phase II therapeutic trial (IFCT-CHIVA 1001) is under way nationally.
    Revue des Maladies Respiratoires 02/2014; 31(2):133-141. · 0.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cirrhosis is a leading cause of death among patients infected with human immunodeficiency virus (HIV). We sought to determine risk factors for and time trends in the prevalence of cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma (HCC) among patients diagnosed with HIV who received care in the Veterans Affairs (VA) health care system nationally between 1996 and 2009 (n = 24,040 in 2009). Among patients coinfected with HIV and hepatitis C virus (HCV), there was a dramatic increase in the prevalence of cirrhosis (3.5%‐13.2%), decompensated cirrhosis (1.9%‐5.8%), and HCC (0.07%‐1.6%). Little increase was observed among patients without HCV coinfection in the prevalence of cirrhosis (1.7%‐2.2%), decompensated cirrhosis (1.1%‐1.2%), and HCC (0.03%‐0.13%). In 2009, HCV infection was present in the majority of patients with HIV who had cirrhosis (66%), decompensated cirrhosis (62%), and HCC (80%). Independent risk factors for cirrhosis included HCV infection (adjusted odds ratio [AOR], 5.82; 95% confidence interval [CI], 5.0‐6.7), hepatitis B virus (HBV) infection (AOR, 2.40; 95% CI, 2.0‐2.9), age (AOR, 1.03; 95% CI, 1.02‐1.04), Hispanic ethnicity (AOR, 1.76; 95% CI, 1.4‐2.2), diabetes (AOR, 1.79; 95% CI, 1.6‐2.1), and alcohol abuse (AOR, 1.78; 95% CI, 1.5‐2.1), whereas black race (AOR, 0.56; 95% CI, 0.48‐0.64) and successful eradication of HCV (AOR, 0.61; 95% CI, 0.4‐0.9) were protective. Independent risk factors for HCC included HCV infection (AOR, 10.0; 95% CI, 6.1‐16.4), HBV infection (AOR, 2.82; 95% CI, 1.7‐4.7), age (AOR, 1.05; 95% CI, 1.03‐1.08), and low CD4+ cell count (AOR, 2.36; 95% CI, 1.3‐4.2). Among 5999 HIV/HCV‐coinfected patients, 994 (18%) had ever received HCV antiviral treatment, of whom 165 (17%) achieved sustained virologic response. Conclusion: The prevalence of cirrhosis and HCC has increased dramatically among HIV‐infected patients driven primarily by the HCV epidemic. Potentially modifiable risk factors include HCV infection, HBV infection, diabetes, alcohol abuse, and low CD4+ cell count. (HEPATOLOGY 2013)
    Hepatology 01/2013; 57(1). · 11.19 Impact Factor